Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review

American Journal of Kidney Diseases

Volumn 51, Issue 2, 2008, Pages 199-211

  Bomback, Andrew S ^a,b   Kshirsagar, Abhijit V ^a   Amamoo, M Ahinee ^a,b   Klemmer, Philip J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

Aldosterone antagonists; angiotensin II type 1 receptor blockers; angiotensin converting enzyme inhibitors; chronic; renal insufficiency; renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; PILOT STUDY; PROTEINURIA; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; PROTEINURIA; RECEPTORS, ANGIOTENSIN; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 38149030811     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.10.040     Document Type: Article

References (61)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
2. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
3. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
4. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361 (2003) 117-124
5. MacKinnon M., Shurraw S., Akbari A., Knoll G.A., Jaffey J., and Clark H.D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48 (2006) 8-20
6. Lysaght M.J. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13 suppl 1 (2002) S37-S40
7. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
8. Staessen J., Lijnen P., Fagard R., Verschueren L.J., and Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 (1981) 457-465
9. Biollaz J., Brunner H.R., Gavras I., Waeber B., and Gavras H. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4 (1982) 966-972
10. Lee A.F., MacFadyen R.J., and Struthers A.D. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: A longitudinal study. Eur J Heart Fail 1 (1999) 401-406
11. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation 100 (1999) 1056-1064
12. Cicoira M., Zanolla L., Rossi A., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37 (2001) 1808-1812
13. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., and Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (2004) 1936-1939
14. Rocha R., Stier Jr. C.T., Kifor I., et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 (2000) 3871-3878
15. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int 66 (2004) 1-9
16. Rocha R., Chander P.N., Zuckerman A., and Stier Jr. C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 (1999) 232-237
17. Greene E.L., Kren S., and Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 (1996) 1063-1068
18. Conn J.W., Knopf R.F., and Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107 (1964) 159-172
19. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 17 (1996) 1-12
20. Chrysostomou A., and Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 (2001) 925-926
21. Epstein M., Buckalew V., Martinez F., et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 15 (2002) 24A (abstr)
22. White W.B., Duprez D., St Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
23. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 (2003) 1148-1155
24. Furumatsu Y., Shoji T., Tomida K., et al. Antiproteinuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker, and spironolactone. J Am Soc Nephrol 14 (2003) 762A (abstr)
25. Nowicki M., Muskala P., Bald E., and Chwatko G. Nephroprotective effect of combined converting enzyme and aldosterone blockade in hypertensive patients with target organ damage is blood pressure-dependent. J Am Soc Nephrol 14 (2003) 21A (abstr)
26. Shiigai T., Kuwana H., Kobayashi T., and Maeda Y. Effect of spironolactone added to angiotensin receptor blocker in renal failure patients. J Am Soc Nephrol 1 (2003) 763A (abstr)
27. Sato A., Hayashi K., Naruse M., and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 (2003) 64-68
28. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
29. Williams G.H., Burgess E., Kolloch R.E., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 (2004) 990-996
30. Rachmani R., Slavachevsky I., Amit M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med 21 (2004) 471-475
31. Nitta K, Uchida K, Nihei H: Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am J Med 117:444-445, 200
32. Furumatsu Y., Shoji T., Hayashi D., et al. Antiproteinuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker, and spironolactone: One year follow up. J Am Soc Nephrol 15 (2004) 58A (abstr)
33. Bianchi S., Bigazzi R., and Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 46 (2005) 45-51
34. Sato A., Hayashi K., and Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18 (2005) 44-49
35. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68 (2005) 2829-2836
36. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., and Parving H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28 (2005) 2106-2112
37. Schjoedt K.J., Rossing K., Tarnow L., and Parving H.H. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. J Am Soc Nephrol 16 (2005) 57A (abstr)
38. van den Meiracker A.H., Baggen R.G., Pauli S., et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 24 (2006) 2285-2292
39. Bianchi S., Bigazzi R., and Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006) 2116-2123
40. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70 (2006) 536-542
41. Chrysostomou A., Pedagogos E., MacGregor A., and Becker G.J. Double-blind, placebo-controlled study on the effect of aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1 (2006) 256-262
42. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces proteinuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006) 940-951
43. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91 (2006) 2214-2217
44. Schulz K.F., Chalmers I., Hayes R.J., and Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995) 408-412
45. Moher D., Pham B., Jones A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998) 609-613
46. Smith G.D., and Egger M. Who benefits from medical interventions?. BMJ 308 (1994) 72-74
47. Glasziou P.P., and Irwig L.M. An evidence based approach to individualising treatment. BMJ 311 (1995) 1356-1359
48. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 9 (1995) 145-149
49. Fullerton M.J., and Funder J.W. Aldosterone and cardiac fibrosis: In vitro studies. Cardiovasc Res 28 (1994) 1863-1867
50. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
51. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
52. Nishiyama A., and Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade. J Pharmacol Sci 100 (2006) 9-16
53. Zhou X., Ono H., Ono Y., and Frohlich E.D. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 24 (2004) 242-249
54. Asai M., Monkawa T., Marumo T., et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 27 (2004) 971-978
55. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., and Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 (2006) 1084-1093
56. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 2 (1996) 47-54
57. Sato A., and Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29 (2001) 13-21
58. Lakkis J., Lu W.X., and Weir M.R. RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5 (2003) 408-417
59. Horita Y., Taura K., Taguchi T., Furusu A., and Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 11 (2006) 462-466
60. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
61. Prakash E.S. "Aldosterone escape" or refractory hyperaldosteronism?. MedGenMed 7 (2005) 25